The purpose of the study is to find the best dose for study drug FG-3246, based on safety and the ability of the study drug to shrink your tumor and delay progression of disease, in men with metastatic castration-resistant prostate cancer.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Young Whang
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Urinary and Bladder
Men's Health
25-1847
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
